Compare Baxter International Inc (BAX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Under Armour Inc Class A — how do they compare? Baxter International Inc trades at $22.38 (market cap $11.26B), while Under Armour Inc Class A trades at $6.92 (market cap $2.79B). The key difference: Baxter International Inc is far larger — about 4× Under Armour Inc Class A's market cap, and Baxter International Inc pays a 0.92% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| BAX | UA | |
|---|---|---|
Market Cap | $11.26B | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.22 | $7.88 |
52-Week Low | $15.80 | $3.96 |
Enterprise Value | $18.93B | $4.42B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Under Armour (UA) trades at $6.61 with a neutral daily performance. The stock shows bullish technical signals from moving averages but faces fundamental challenges with negative net income margins (-9.98%) and declining revenue projections for 2026. Recent earnings showed mixed results with a Q1 2026 miss, while analyst sentiment remains divided with 40.3% buy ratings. The company's cash flow trends show significant outflows, with net cash flow negative $361.87 million in 2025.
The outlook remains cautious due to ongoing revenue declines and profitability challenges, though technical strength and institutional buying by investors like Prem Watsa provide some support. Key risks include sustained negative earnings, competitive pressures, and execution of the company's turnaround strategy. The stock presents a speculative opportunity for investors believing in management's premium product focus and inventory discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
